Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Abida Babu, Kathryn Bower, Madiha Siraj, Biwei Cao, Jongphil Kim, Hany Elmariah, Rawan Faramand, Sayeef Mirza, Lia Perez, Asmita Mishra, Farhad Khimani, Jose L. Ochoa-Bayona, Michael Nieder, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan

Blood (2024) 144 (Supplement 1): 4881.

https://doi.org/10.1182/blood-2024-202709

Published: 2024

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes

David Sallman, Amy F McLemore, Rami S. Komrokji, Hany Elmariah, Andrew T. Kuykendall, Nelli Bejanyan, Onyee Chan, Rawan Faramand, Joseph A. Pidala, Sean J. Yoder, Lia Perez, Taiga Nishihori, Eric Padron, Hugo Francisco Fernandez, Jeffrey E Lancet, Asmita Mishra

Blood (2024) 144 (Supplement 1): 1046.

https://doi.org/10.1182/blood-2024-203903

Published: 2024

Journal Articles

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Blood (2024) 144 (Supplement 1): 695.

https://doi.org/10.1182/blood-2024-200833

Published: 2024

Journal Articles

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 4826.

https://doi.org/10.1182/blood-2024-202363

Published: 2024

Journal Articles

Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis

Blood (2024) 144 (Supplement 1): 4911.

https://doi.org/10.1182/blood-2024-205572

Published: 2024

Journal Articles

Cytokines associated with organ manifestations in chronic graft-versus-host disease

Stephanie J. Lee, Ningxin Ma, Timothy Randolph, Carrie L. Kitko, Corey S. Cutler, Najla El Jurdi, George Chen, Betty K. Hamilton, Joseph A. Pidala, Paul A Carpenter, Sally Arai, Lynn Onstad, Sophie Paczesny, Tomoko Sekiguchi, Motoko Koyama, Geoffrey R. Hill

Blood (2024) 144 (Supplement 1): 4902.

https://doi.org/10.1182/blood-2024-203743

Published: 2024

Journal Articles

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Blood (2024) 144 (Supplement 1): 4871.

https://doi.org/10.1182/blood-2024-208229

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

Journal Articles

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2024-209164

Published: 2024

Journal Articles

Chronic graft-versus-host disease: unresolved complication or ancient history?

Joseph A. Pidala, Ted A. Gooley, Leo Luznik, Bruce R. Blazar

Blood (2024) 144 (13): 1363–1373.

https://doi.org/10.1182/blood.2023022735

Published: 2024

Includes: Supplemental data

Journal Articles

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Teresa Caprice, Wenyi Fan, Jongphil Kim, Rawan Faramand, Asmita Mishra, Lia Perez, Farhad Khimani, Aleksandr Lazaryan, Jose L. Ochoa-Bayona, Hien Liu, Michael D. Jain, Michael Nieder, Claudio Anasetti, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan, Hany Elmariah

Blood (2023) 142 (Supplement 1): 390.

https://doi.org/10.1182/blood-2023-186738

Published: 2023

Journal Articles

Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report

Nelli Bejanyan, Hany Elmariah, Kayla Reid, Bin Yu, Jongphil Kim, Cheryl Cox, Melissa Lowden, Rawan Faramand, Christopher Cubitt, Hien Liu, Justin Boucher, Jose Alejandro Guevara, David A Sallman, Jeffrey Lancet, Joseph A. Pidala, Kumar Karyampudi, Frederick L. Locke, Claudio Anasetti, Marco Davila

Blood (2023) 142 (Supplement 1): 4846.

https://doi.org/10.1182/blood-2023-187058

Published: 2023

Journal Articles

Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia

Vivian Irizarry Gatell, Denise Kalos, Joseph A. Pidala, Hany Elmariah, Farhad Khimani, Asmita Mishra, Taiga Nishihori, Michael D. Jain, Michael Neider, Lia Perez, Sayeef Mirza, Bijal D. Shah, Leidy Lismeris Isenalumhe, Nelli Bejanyan, Aleksandr Lazaryan, Rawan Faramand

Blood (2023) 142 (Supplement 1): 2830.

https://doi.org/10.1182/blood-2023-180321

Published: 2023

Journal Articles

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Hany Elmariah, Jongphil Kim, Asmita Mishra, Rawan Faramand, Lia Perez, Aleksandr Lazaryan, Farhad Khimani, Hien Liu, Jose L. Ochoa-Bayona, Michael Nieder, Nicholas Figura, Timothy J Robinson, Taiga Nishihori, Claudio Anasetti, Joseph A. Pidala, Nelli Bejanyan

Blood (2023) 142 (Supplement 1): 4900.

https://doi.org/10.1182/blood-2023-187473

Published: 2023

Journal Articles

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Ryan James Caddell, PharmD, Braydon Schaible, MPH, Zhenjun Ma, PhD, Elizabeth Dimaggio, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Claudio Anasetti, MD, Ernesto Ayala, MD, Brian C. Betts, MD, Mohamed A. Kharfan-Dabaja, MD, Frederick L. Locke, MD, Taiga Nishihori, MD, Joseph A. Pidala, MD, Hugo F. Fernandez, MD, Asmita Mishra, MD

Blood (2016) 128 (22): 3486.

https://doi.org/10.1182/blood.V128.22.3486.3486

Published: 2016

Journal Articles

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Blood (2016) 128 (22): 505.

https://doi.org/10.1182/blood.V128.22.505.505

Published: 2016

Journal Articles

Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes

Anita J Kumar, MDMS, Soyoung Kim, PhD, Michael Hemmer, MS, Mukta Arora, MD, Steve Spellman, MBS, Joseph A. Pidala, MD, Daniel Couriel, MD MS, Amin M. Alousi, MD, Alison W Loren, MD MS

Blood (2016) 128 (22): 70.

https://doi.org/10.1182/blood.V128.22.70.70

Published: 2016

Journal Articles

Influence of Age on Risk for Acute and Chronic Graft Versus Host Disease in Children Receiving HLA Identical Sibling Bone Marrow Transplantation

Muna Qayed, MD MSc, John Horan, MD MPH, Stephen R. Spellman, MBS, Mukta Arora, MD, Tao Wang, PhD, Michael Hemmer, MS, Joseph A Pidala, MD, PhD, Daniel Couriel, MD MS, Amin M. Alousi, MD

Blood (2016) 128 (22): 2228.

https://doi.org/10.1182/blood.V128.22.2228.2228

Published: 2016

Journal Articles

Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations

Sarah Nikiforow, MD PhD, Michael Hemmer, MS, Stephen R. Spellman, MBS, Amin M. Alousi, MD, Daniel R. Couriel, MD, Joseph A Pidala, MD, PhD, Mukta Arora, MD, Corey S Cutler, MD MPH, Tao Wang, PhD

Blood (2015) 126 (23): 857.

https://doi.org/10.1182/blood.V126.23.857.857

Published: 2015

NARROW

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis

Cytokines associated with organ manifestations in chronic graft-versus-host disease

Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Chronic graft-versus-host disease: unresolved complication or ancient history?

Post-Transplant Cyclophosphamide Equalizes Clinical Outcomes of Allogeneic Hematopoietic Cell Transplantation across Racial and Ethnic Populations

Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report

Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia

Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes

Influence of Age on Risk for Acute and Chronic Graft Versus Host Disease in Children Receiving HLA Identical Sibling Bone Marrow Transplantation

Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only